A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.


Updates from The Motley Fool

Latest updates on Alkermes from Fool.com.  The Fool has written over 100 articles on Alkermes.
5 Biotech Predictions for 2016

A win and loss for marijuana, a big advance in Alzheimer's disease, and the next big thing are am...

This Week in Biotech

A late-stage trial stopped early due to highly statistically significant efficacy, a major biopha...

Tackling Pain and Addiction

Alkermes offers more than schizophrenia and MS treatments: Its research into addiction and pain m...

This Week in Biotech

An FDA approval, a promising drugs' late-stage failure, and a biopharmaceutical company reinventi...

Say Hello to the New Alkermes

Even biotechnology stocks could use a facelift now and then. Alkermes CEO Richard Pops outlines t...



Stock Performance

View Interactive ALKS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alkermes.
Current Price: $52.57
Prev Close: $53.29
Open: $52.91
Bid: $51.00
Ask: $55.00
Day's Range: $51.84 - $53.20
52wk Range: $27.14 - $60.74
Volume: 776,962
Avg Vol 858,159
Market Cap: $8B
P/E (ttm): -38.62
EPS (ttm): ($1.38)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alkermes.
CAPS Rating 5 out of 5
 
320 Outperform
12 Underperform
CAPS All Stars
 
88 Outperform
2 Underperform

How do you think Alkermes will perform against the market?



You pick for Alkermes is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Richard F. Pops, CEO

100% Approve

Based on 33 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alkermes.

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers